Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 187-199

  Bonn, Britta ^a,b   Masimirembwa, Collen M ^b,c   Castagnoli Jr , Neal ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c African Institute of Biomedical Science and Technology   (Zimbabwe)

^d EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HEME; LEVALLORPHAN; LEVORPHANOL; MIDAZOLAM; RECOMBINANT ENZYME;

ARTICLE; CATALYST; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; METABOLITE; MOLECULAR MODEL; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

BIOCATALYSIS; CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; HYDROPHOBICITY; KINETICS; LEVALLORPHAN; LEVORPHANOL; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STATIC ELECTRICITY; TANDEM MASS SPECTROMETRY; THERMODYNAMICS;

EID: 73149096034     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028670     Document Type: Article

References (26)

1. Benetton SA, Borges VM, Chang TK, and McErlane KM (2004) Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica 34: 335-344.
2. Coutts RT, Su P, and Baker GB (1994) Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 31:177-186.
3. de Groot MJ, Bijloo GJ, Martens BJ, van Acker FA, and Vermeulen NP (1997) A refined substrate model for human cytochrome P450 2D6. Chem Res Toxicol 10:41-48.
4. De Rienzo F, Fanelli F, Menziani MC, and De Benedetti PG (2000) Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 14:93-116.
5. Ekroos M and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103:13682-13687.
6. Flanagan JU, Maréchal JD, Ward R, Kemp CA, McLaughlin LA, Sutcliffe MJ, Roberts GC, Paine MJ, and Wolf CR (2004) Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J 380:353-360.
7. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454.
8. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857.
9. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-204.
10. Guengerich FP, Hanna IH, Martin MV, and Gillam EM (2003) Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 42:1245-1253.
11. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, and Somogyi AA (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57:287-297.
12. Kirkwood LC, Nation RL, and Somogyi AA (1997) Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44:549-555.
13. Kjellander B, Masimirembwa CM, and Zamora I (2007) Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach. J Chem Inf Model 47:1234-1247.
14. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, and Donné-Op den Kelder GM (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219.
15. Lewis DF (1999) Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Exp Toxicol Pathol 51:369-374.
16. Lewis DF, Eddershaw PJ, Goldfarb PS, and Tarbit MH (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27:319-339.
17. Lussenburg BM, Keizers PH, de Graaf C, Hidestrand M, Ingelman-Sundberg M, Vermeulen NP, and Commandeur JN (2005) The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent. Biochem Pharmacol 70:1253-1261.
18. Narimatsu S, Arai T, Masubuchi Y, Horie T, Hosokawa M, Ueno K, Kataoka H, Yamamoto S, Ishikawa T, and Cho AK (2001) Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol Pharm Bull 24:988-994.
19. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC, and Wolf CR (2003) Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021-4027.
20. Poulos TL, Finzel BC, and Howard AJ (1987) High-resolution crystal structure of cytochrome P450cam. J Mol Biol 195:687-700.
21. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622.
22. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, and Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997-1004.
23. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
24. Yamazaki H and Shimada T (1998) Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 26:1053-1057.
25. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091- 38094.
26. Yue QY and Säwe J (1997) Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 52:41-47.